Ethyl 7-chloro-2-oxoheptanoate

What is Ethyl 7-chloro-2-oxoheptanoate , cas no. 78834-75-0,a producer telling you the result.

                                                        CAS NO. 78834-75-0

 If you need the products .Please send your inquiry to us through    e-mail    info@pewax.com.cn

 

To begin with, let us tell you what is the basic information of  Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0 ?

 

Molecular Weight

206.66700

Molecular Formula

C9H15ClO3

Density

1.093 g/cm3

Boiling Point

281.2ºC at 760 mmHg

LogP

1.91780

CAS Number

78834-75-0

MDL No.

MFCD07698675

Flash Point

111.3ºC

Like many stuff, it has many synonyms as follows

EINECS 278-992-1

ethyl 7-chloro-2-oxoheptanoate

 

The chemical is very special

 

If you need the products .Please send your inquiry to us through    e-mail    info@pewax.com.cn

 

Computational Chemistry Data

 

1. Reference value for hydrophobic parameter calculation (XlogP): 2

2. Number of hydrogen bond donors: 0

3. Number of hydrogen bond receptors: 3

4. Number of rotatable chemical bonds: 8

5. Number of tautomers: 2

6. Topological molecule polarity surface area: 43.4

7. Number of heavy atoms: 13

8. Surface charge: 0

9. Complexity: 168

10. Number of Isotope Atoms: 0

11. Determine the number of atomic structure centers: 0

12. Number of uncertain atomic structure centers: 0

13. Determine the number of chemical bond stereocenters: 0

14. Number of uncertain chemical bond stereocenters: 0

15. Number of covalent bond units: 1

 

Second, the Synthetic Route we will recommend is the most important for your reference?

 

First, synthesis line of Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0 ,as follows

 

If you need the products .Please send your inquiry to us through    e-mail    info@pewax.com.cn

 

Ethyl 7-chloro-2-oxoheptoate was synthesized from 1-bromo-5-chloropentane and diethyl acetate in a yield of approximately 88%;

 

Synthesis line in lab as below

Step 1: Under dry N2 protection, burn in a four port furnace equipped with a condensing tube, thermometer, stirrer, and 50ml constant pressure drip funnel .Add a mixture of 7.3g of diethyl oxalate, 9.3g of 1-bromo-5-chloropentane, and 30ml of tetrahydrofuran to the bottle;

 

Step 2: Quickly add 1.0g PSIM MgBr under the condition of -25 , and maintain the reaction temperature controlled at around -10 during the drop addition reaction. After the drop addition is completed, continue the reaction for 1 hour;

 

Step 3: Hydrolyze with 15ml of 4M hydrochloric acid, and ensure that the reaction temperature is below 0 during the acid hydrolysis process;Separate the organic layer, extract the water layer with dichloromethane, wash with saturated sodium chloride solution, and add NaHS03 saturated solution for oscillation;

 

Step 4: After shaking, the organic layer and water layer are neutralized with a saturated NaHC03 solution. The organic layer is rotated and evaporated to produce tetrahydrofuran. The organic layer is merged and neutralized with saturated NaHC03, washed with NaHS03, and then washed with NaCl until neutral. The solvent is evaporated and reduced pressure distillation is carried out to obtain 7-chloro-2-oxoheptate ethyl ester.

 

Second,synthesis line of  Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0 ,as follows

 

Synthesis of 7-chloro-2-oxoheptoate ethyl ester using diethyl acetate in a yield of approximately 74%;

 

Other synthesis lines of Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0 as follows

 

 

Third, what is the usage of Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0  pleas see below

 

Main Usage:

Ethyl 7-chloro-2-oxoheptoate is an important starting material for the synthesis of Cilastatin. Silastatin is a kidney dehydrogenase inhibitor developed by an American company. It can inhibit the renal metabolism of the broad-spectrum antibacterial drug imipenem, which is currently used in clinical practice. While reducing renal toxicity, it can also increase the blood antibacterial concentration of imipenem, with significant therapeutic effects. Therefore, in the past decade, domestic and foreign chemists have conducted extensive research on how to improve the purity and yield of synthesized silastatin. Due to the fact that ethyl 7-chloro-2-oxoheptoate is an important starting material for the synthesis of cilastatin, and the purity of the raw material is an important factor affecting the product cilastatin, obtaining high-purity and high-yield ethyl 7-chloro-2-oxoheptoate has become the key to improving the purity of cilastatin and reducing the production cost of the drug.

 

If you need the products .Please send your inquiry to us through    e-mail    info@pewax.com.cn


Other usages as below

 

One kind of raw material for producing cilastatin cas no 82009-34-5,which is as follows

 

 

Besides Safety Information of Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0  is also important when handling it

Hazard Codes

Xi

H.S. Code

2918300090

 

What is the appearance of  Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0 ?   Please see the picture of Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0  below

 

If you need the products .Please send your inquiry to us through    e-mail    info@pewax.com.cn

 

Specification of Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0 is below

Apperance:yellow oil liquid

Assay: 98 % min by GC

IR identity: conform

Water by KF:0.5% max.


HNMR  picture of  Ethyl 7-chloro-2-oxoheptanoate Cas No. 78834-75-0   is as follows,

 

 

Reference of  Article cited for your reference below,

(1)Ethyl 7-chloro-2-oxoheptanoate

(2)High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway       in Skeletal Muscle

     Publication Name: ACS Chemical Biology

     Publication Date: 2020-05-27

     PMID: 32459468

     DOI: 10.1021/acschembio.0c00343

(3)A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity

Publication Name: Antiviral Research

Publication Date: 2020-01

PMID: 31786250

DOI: 10.1016/j.antiviral.2019.104667